RemeGen Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

RemeGen's earnings have been declining at an average annual rate of -28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 44.5% per year.

Wichtige Informationen

-28.7%

Wachstumsrate der Gewinne

-15.7%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	11.0%
Wachstumsrate der Einnahmen	44.5%
Eigenkapitalrendite	-65.5%
Netto-Marge	-102.0%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

Sep 28

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Jul 22

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Oct 16

A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Aug 24

Aufschlüsselung der Einnahmen und Ausgaben

Wie RemeGen Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

SEHK:9995 Einnahmen, Ausgaben und Erträge (CNY Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	1,522	-1,552	1,162	1,602
30 Jun 24	1,402	-1,588	1,111	1,572
31 Mar 24	1,245	-1,536	1,119	1,388
31 Dec 23	1,083	-1,511	1,087	1,306
30 Sep 23	972	-1,341	1,059	1,178
30 Jun 23	844	-1,213	973	1,073
31 Mar 23	790	-1,036	821	1,014
31 Dec 22	772	-999	718	982
30 Sep 22	1,879	276	642	849
30 Jun 22	1,745	231	582	834
31 Mar 22	1,570	174	543	793
31 Dec 21	1,424	276	483	711
30 Sep 21	115	-912	378	663
30 Jun 21	29	-892	338	604
31 Mar 21	4	-783	291	527
31 Dec 20	0	-698	242	466
30 Sep 20	0	-588	175	423
30 Jun 20	0	-478	109	380
31 Mar 20	0	-442	84	358
31 Dec 19	0	-430	69	352
31 Dec 18	11	-270	29	216

Qualität der Erträge: 9995 is currently unprofitable.

Wachsende Gewinnspanne: 9995 is currently unprofitable.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 9995 is unprofitable, and losses have increased over the past 5 years at a rate of 28.7% per year.

Beschleunigtes Wachstum: Unable to compare 9995's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: 9995 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).

Eigenkapitalrendite

Hohe Eigenkapitalrendite: 9995 has a negative Return on Equity (-65.52%), as it is currently unprofitable.

RemeGen Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings released: CN¥0.54 loss per share (vs CN¥0.61 loss in 3Q 2023)

RemeGen Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.80 loss per share (vs CN¥0.70 loss in 2Q 2023)

RemeGen Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.54 loss per share (vs CN¥0.61 loss in 3Q 2023)

Non-Executive Director recently sold HK$3.4m worth of stock

New major risk - Share price stability

RemeGen Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified

New major risk - Market cap size

Consensus EPS estimates fall by 20%, revenue upgraded

New major risk - Financial position

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings released: CN¥0.80 loss per share (vs CN¥0.70 loss in 2Q 2023)

RemeGen Co., Ltd. Announces First Patient Enrollment in the U.S for Its Global Multi-Center Phase III Clinical Trial for the Treatment of Generalized Myasthenia Gravis

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

RemeGen Co., Ltd. Announces Full Approval of Telitacicept for the Treatment of Patients with Rheumatoid Arthritis by NMPA

New minor risk - Profitability

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

New minor risk - Profitability

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer At ESGO 2024

Full year 2023 earnings released: CN¥2.86 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

New minor risk - Share price stability

RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA

RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology

Third quarter 2023 earnings released

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Second quarter 2023 earnings released: CN¥0.70 loss per share (vs CN¥0.38 loss in 2Q 2022)

RemeGen Co., Ltd. Announces Results of Phase III Study on Telitacicept for Treatment of Rheumatoid Arthritis in China

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Now 20% undervalued after recent price drop

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Remegen Co., Ltd. Receives Ethics Approval for the Phase I Clinical Trial in Australia

Now 21% undervalued after recent price drop

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Full year 2022 earnings released: CN¥1.81 loss per share (vs CN¥0.57 profit in FY 2021)

Now 20% undervalued

RemeGen Co., Ltd. Announces FDA Approves Ind Application for Telitacicept for Treatment of gMG and Grants It Fast Track Designation

National Medical Products Administration Approves IND Application for RemeGen’s Disitamab Vedotin for Injection, Given Intravenously, in Combination with Gemcitabine Hydrochloride for Injection, Given Intravesically, for Treatment of NMIBC

RemeGen Co., Ltd.'s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

Less than half of directors are independent

RemeGen Co., Ltd. Announces Telitacicept Propose to Grant Telitacicept Breakthrough Therapy Designation for the Treatment of Generalised Myasthenia Gravis

RemeGen Co., Ltd. Announces Results of Phase Ii Clinical Study of Telitacicept for Treatment of Myasthenia Gravis (MG) in China

Third quarter 2022 earnings released: CN¥0.37 loss per share (vs CN¥0.74 profit in 3Q 2021)

RemeGen Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Remegen Co., Ltd. Receives Orphan Drug Designation from FDA for Treatment of Myasthenia Gravis

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China

Second quarter 2022 earnings released

RemeGen Co., Ltd. to Report Q2, 2022 Results on Aug 26, 2022

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director